firocoxib has been researched along with Canine Diseases in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (45.45) | 29.6817 |
| 2010's | 9 (40.91) | 24.3611 |
| 2020's | 3 (13.64) | 2.80 |
| Authors | Studies |
|---|---|
| Beal, MW; Carter, DL; Levy, NA; Pfeifer, JM | 1 |
| Ikeda, M; Kimura, J; Kishimoto, M; Kondo, H; Kushida, K; Ohmori, K; Okazawa, T; Osada, H | 1 |
| Beugnet, F; de Salazar Alcalá, AG; Dehman, A; Gioda, L | 1 |
| Beale, B; Jarudecha, T; Kashemsant, N; Kwananocha, I; Lascelles, BDX; Lekcharoensuk, C; Peirone, B; Vijarnsorn, M | 1 |
| Geum, M; Kim, HJ; Ko, HY; Na, YJ | 1 |
| Conzemius, MG; Davila, D; Evans, RB; Keeshen, TP | 1 |
| Abramo, F; Albanese, F; Caporali, C; Millanta, F; Vichi, G | 1 |
| Brain, PH; Dunn, AL; Greenwell, CM | 1 |
| Arenas, C; Granados-Soler, JL; Peña, L; Pérez-Alenza, MD | 1 |
| Budsberg, SC; Punke, JP; Reynolds, LR; Speas, AL | 1 |
| Joubert, KE | 1 |
| Lecoindre, O; Pepin-Richard, C | 1 |
| Asimus, E; Autefage, A; Palissier, FM; Pepin-Richard, C | 1 |
| Al-Nadaf, S; Budsberg, SC; Cathcart, CJ; Johnston, SA; Reynolds, LR | 1 |
| Andersen, DR; Black, WC; Brideau, C; Hanson, PD; Hickey, GJ; McCann, ME; Zhang, D | 1 |
| Carithers, D; Moldave, K; Ryan, WG | 1 |
| Alva, R; Bell, L; Brooks, KC; Case, J; Conzemius, M; Drag, M; Fleishman, C; Gordon, W; Hanson, PD; Romano, D; Schuessler, J; Shelley, B; Sifferman, R | 1 |
| Fleishman, C; Hanson, PD; Pollmeier, M; Toulemonde, C | 1 |
| Overgaauw, P | 1 |
| Hanson, PD; Hazewinkel, HA; Pollmeier, M; Theyse, LF; van den Brom, WE | 1 |
| Drag, M; Hanson, PD; Kunkle, BN; Romano, D | 1 |
| Ferreira, TH; Luna, SP; Mantovani, FB; Moutinho, FQ; Salcedo, ES; Steagall, PV | 1 |
13 trial(s) available for firocoxib and Canine Diseases
| Article | Year |
|---|---|
Assessment of the efficacy of firocoxib (Previcox®) and grapiprant (Galliprant®) in an induced model of acute arthritis in dogs.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Dog Diseases; Dogs; Lameness, Animal; Random Allocation; Sulfones; Sulfonylurea Compounds; Uric Acid | 2019 |
The effectiveness of marine based fatty acid compound (PCSO-524) and firocoxib in the treatment of canine osteoarthritis.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dinoprostone; Dog Diseases; Dogs; Double-Blind Method; Drug Therapy, Combination; Fatty Acids, Unsaturated; Female; Gait; Male; Osteoarthritis; Pain; Pain Measurement; Prospective Studies; Sulfones | 2019 |
Comparison of the analgesic efficacy of perioperative firocoxib and tramadol administration in dogs undergoing tibial plateau leveling osteotomy.
Topics: 4-Butyrolactone; Animals; Dog Diseases; Dogs; Female; Hydrocortisone; Male; Osteotomy; Pain Measurement; Pain, Postoperative; Sulfones; Time Factors; Tramadol | 2013 |
Clinical outcome and cyclo-oxygenase-2 expression in five dogs with solar dermatitis/actinic keratosis treated with firocoxib.
Topics: 4-Butyrolactone; Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dog Diseases; Dogs; Female; Gene Expression Regulation, Enzymologic; Keratosis, Actinic; Male; Sulfones | 2013 |
Effects of firocoxib, meloxicam, and tepoxalin on prostanoid and leukotriene production by duodenal mucosa and other tissues of osteoarthritic dogs.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Duodenum; Female; Intestinal Mucosa; Leukotrienes; Male; Meloxicam; Osteoarthritis; Prostaglandins; Pyrazoles; Sulfones; Synovial Fluid; Thiazines; Thiazoles | 2008 |
The effects of firocoxib (Previcox) in geriatric dogs over a period of 90 days.
Topics: 4-Butyrolactone; Aging; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Chemical Analysis; Dog Diseases; Dogs; Female; Lameness, Animal; Male; Osteoarthritis; Pain; Severity of Illness Index; Sulfones; Treatment Outcome | 2009 |
Efficacy of ABT-116, an antagonist of transient receptor potential vanilloid type 1, in providing analgesia for dogs with chemically induced synovitis.
Topics: 4-Butyrolactone; Analgesia; Animals; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Female; Indazoles; Injections, Intra-Articular; Lameness, Animal; Male; Phenylurea Compounds; Stifle; Sulfones; Synovitis; TRPV Cation Channels; Uric Acid | 2012 |
Clinical effectiveness and safety of a new NSAID, firocoxib: a 1,000 dog study.
Topics: 4-Butyrolactone; Age Factors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Female; Male; Osteoarthritis; Safety; Sex Factors; Sulfones; Treatment Outcome | 2006 |
Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Etodolac; Female; Lameness, Animal; Male; Osteoarthritis; Range of Motion, Articular; Safety; Sulfones; Treatment Outcome | 2006 |
Clinical evaluation of firocoxib and carprofen for the treatment of dogs with osteoarthritis.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Dog Diseases; Dogs; Double-Blind Method; Female; Male; Osteoarthritis; Sulfones; Tablets; Treatment Outcome | 2006 |
Comparison of the effects of firocoxib, carprofen and vedaprofen in a sodium urate crystal induced synovitis model of arthritis in dogs.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Carbazoles; Cross-Over Studies; Dog Diseases; Dogs; Female; Lameness, Animal; Male; Naphthalenes; Propionates; Sulfones; Synovitis; Time Factors; Uric Acid | 2008 |
Firocoxib efficacy preventing urate-induced synovitis, pain, and inflammation in dogs.
Topics: 4-Butyrolactone; Animals; Carbazoles; Cyclooxygenase 2 Inhibitors; Dog Diseases; Dogs; Female; Lameness, Animal; Male; Meloxicam; Severity of Illness Index; Sulfonamides; Sulfones; Synovitis; Thiazines; Thiazoles; Treatment Outcome; Uric Acid | 2007 |
Evaluation of the adverse effects of oral firocoxib in healthy dogs.
Topics: 4-Butyrolactone; Administration, Oral; Animals; Blood Chemical Analysis; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Dog Diseases; Dogs; Drug Hypersensitivity; Endoscopy, Gastrointestinal; Female; Male; Occult Blood; Sulfones | 2007 |
9 other study(ies) available for firocoxib and Canine Diseases
| Article | Year |
|---|---|
Gastric or duodenal perforation and secondary septic peritonitis following therapeutic nonsteroidal anti-inflammatory drug administration.
Topics: Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Meloxicam; Peritonitis; Retrospective Studies | 2022 |
Toceranib phosphate and firocoxib-mediated partial response in a dog with advanced intranasal sarcoma.
Topics: Animals; Dog Diseases; Dogs; Indoles; Male; Sarcoma; Vascular Endothelial Growth Factor A | 2023 |
Cutaneous adverse drug reaction in a dog following firocoxib treatment.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Drug-Related Side Effects and Adverse Reactions; Female; Sulfones | 2021 |
Metaphyseal osteopathy in three Australian Kelpie siblings.
Topics: 4-Butyrolactone; Animals; Australia; Bone Diseases, Developmental; Dog Diseases; Dogs; Fatal Outcome; Female; Histocytochemistry; Lameness, Animal; Male; Prednisolone; Radiography; Siblings; Sulfones | 2014 |
Adjuvant therapy for highly malignant canine mammary tumours: Cox-2 inhibitor versus chemotherapy: a case-control prospective study.
Topics: 4-Butyrolactone; Animals; Antineoplastic Agents; Case-Control Studies; Chemotherapy, Adjuvant; Cyclooxygenase 2 Inhibitors; Dog Diseases; Dogs; Female; Mammary Neoplasms, Animal; Mitoxantrone; Prospective Studies; Sulfones; Treatment Outcome | 2016 |
Tolerance of firocoxib in dogs with osteoarthritis during 90 days.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Creatinine; Dog Diseases; Dogs; Female; Male; Osteoarthritis; Sulfones; Treatment Outcome; Urea | 2011 |
Long-term efficacy and safety of firocoxib in the treatment of dogs with osteoarthritis.
Topics: 4-Butyrolactone; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Female; Lameness, Animal; Male; Osteoarthritis; Prospective Studies; Severity of Illness Index; Sulfones; Treatment Outcome | 2011 |
In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Cyclooxygenase Inhibitors; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Sulfonamides; Sulfones; Synovitis | 2004 |
[European symposium about osteoarthritis in a dog].
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Dog Diseases; Dogs; Europe; Osteoarthritis; Physical Therapy Modalities; Sulfones; Treatment Outcome | 2007 |